Posted: Tuesday, July 11, 2023
According to the results of the CARTITUDE-4 trial, presented as a Plenary Session at the European Hematologic Association (EHA) 2023 Hybrid Congress (Abstract S100), the use of the dual-binding, B-cell maturation antigen–targeting, chimeric antigen receptor T-cell therapy ciltacabtagene autoleucel improved patients’ progression-free survival. These findings, in addition to the favorable benefit/risk profile across patient populations, suggest the potential of ciltacabtagene autoleucel in the treatment of patients with multiple myeloma after first relapse, explained Hermann Einsele, MD, FRCP, of Universitätsklinikum Würzburg, Germany, and colleagues.
A total of 419 patients with multiple myeloma refractory to lenalidomide therapy were recruited for the study. All patients had received at least three previous lines of therapy and underwent apheresis before beginning treatment. Patients were randomly assigned to receive ciltacabtagene autoleucel (n = 208) or the standard-of-care treatment regimen (n = 211) with either the combination of pomalidomide, bortezomib, and dexamethasone (PVd, n = 28) or daratumumab, pomalidomide, and dexamethasone (DPd, n = 183).
The study authors reported a 74% decrease in the risk of disease progression or death in patients treated with ciltacabtagene autoleucel (hazard ratio [HR] = 0.26). In addition, patients treated with ciltacabtagene autoleucel had improved overall measurable residual disease rates, rates of complete response, and overall response rates compared with patients who received the standard-of-care combination therapy regimens (HR = 0.78).
Furthermore, grade 3 or 4 adverse events were identified in 97% and 94% of patients treated with ciltacabtagene autoleucel and the standard-of-care combination treatments, respectively. They included cytopenias (94% vs. 86%, respectively) and infections (27% vs. 25%, respectively).
Disclosure: Disclosure information for the study authors was not provided.